Kiniksa Pharmaceuticals International, plc cotiza a 78.53 USD y tiene una capitalización bursátil de $6.1B. En los últimos 12 meses ha facturado $754M con un margen de flujo de caja libre del 20.1%. Cotiza a 37.3 veces su flujo de caja libre (P/FCF) y a un PER de 83.9. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinfl…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.30 | $0.27 | $0.17 |
| Estimado | $0.35 | $0.28 | $0.16 | $0.40 |
| Sorpresa | — | +7.1% | +68.8% | -57.5% |
| Métrica | KNSA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 88.5% | 57.0% | +31.5% |
| Operating Margin | 11.4% | -38.6% | +50.0% |
| Net Margin | 8.7% | -33.6% | +42.3% |
| FCF Margin | 20.1% | -13.9% | +34.0% |
| ROE | 10.4% | -40.4% | +50.8% |
| ROA | 7.7% | -32.0% | +39.7% |
| Current Ratio | 3.79 | 2.84 | +0.95 |
| Debt / Equity | — | 0.28 | — |